SLN360
Silence Therapeutics
[]
$sln silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting 
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft